How lung cell factors can improve lung cancer treatment
Official title: Immunoregulatory role of lung-resident club cell factors in lung cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-11017770 · Data updated 2026-11-12
This study is looking at how certain lung cells can help make cancer treatments work better for people with non-small cell lung cancer by using a combination of low-dose radiation and immune therapy, with the goal of improving patient outcomes and survival rates.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $611,239 |
| NIH project number | 5R01CA271545-03 |
| Project ID | NIH-11017770 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing treatment with immune checkpoint inhibitors.
✕Less likely to help
Patients with other types of lung cancer or those who are not receiving immune checkpoint inhibitors may not benefit from this research.
What this research studies
This research investigates the role of lung-resident club cell factors in enhancing the effectiveness of immune checkpoint inhibitors for treating non-small cell lung cancer (NSCLC). The study focuses on understanding how these factors can inhibit immunosuppressive cells in the tumor microenvironment, which often hinder treatment success. By combining low-dose radiation therapy with immune checkpoint inhibitors, the research aims to activate specific lung cell secretions that may lead to better patient outcomes. The approach includes analyzing patient responses to treatment and identifying biomarkers that correlate with improved survival rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer, potentially improving survival rates for patients.
How similar studies have gone: Previous research has shown promising results in enhancing cancer treatment efficacy through similar approaches, indicating potential for success in this study.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Mittal, Vivek — Weill Medical Coll of Cornell Univ
- Study coordinator: Mittal, Vivek
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.